HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
14.96
+0.07 (0.47%)
Feb 10, 2026, 4:00 PM EST - Market closed
HUTCHMED (China) Employees
HUTCHMED (China) had 1,780 employees as of June 30, 2025.
Employees
1,780
Change
n/a
Growth
n/a
Revenue / Employee
$338,313
Profits / Employee
$262,293
Market Cap
2.57B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 1,780 | - | - |
| Dec 31, 2024 | 1,811 | -177 | -8.90% |
| Dec 31, 2023 | 1,988 | -37 | -1.83% |
| Dec 31, 2022 | 2,025 | 265 | 15.06% |
| Dec 31, 2021 | 1,760 | 480 | 37.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,700 |
| Perrigo Company | 8,379 |
| Phibro Animal Health | 2,475 |
| Alvotech | 1,012 |
| ANI Pharmaceuticals | 897 |
| Supernus Pharmaceuticals | 674 |
| Prestige Consumer Healthcare | 600 |
| Dynavax Technologies | 405 |
HCM News
- 5 days ago - HUTCHMED to Announce 2025 Final Results - GlobeNewsWire
- 4 weeks ago - HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet - GlobeNewsWire
- 4 weeks ago - Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 - Benzinga
- 5 weeks ago - HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China - GlobeNewsWire
- 5 weeks ago - HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma - GlobeNewsWire
- 6 weeks ago - HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification - GlobeNewsWire
- 6 weeks ago - HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma - GlobeNewsWire
- 2 months ago - HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors - GlobeNewsWire